Amantadine

CHEMBL660 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

151.2 g/mol

LogP

2.4

Phase

4

An antiviral and dopaminergic medication with dual uses: it was originally developed to prevent influenza A infection, and it also treats the symptoms of Parkinson's disease and drug-induced movement disorders by increasing dopamine activity and blocking NMDA glutamate receptors in the brain. It can reduce involuntary movements (dyskinesias) in Parkinson's patients.

分子量

151.2500 g/mol

LogP

2.40

TPSA

26.00 Å²

Lipinski 五规则

符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Respiratory Disease Pain Management Non-Small Cell Lung Cancer Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Melanoma Oncology Systemic Lupus Erythematosus Multiple Sclerosis Stroke Type 2 Diabetes Major Depressive Disorder Breast Cancer Chronic Pain Hepatitis C Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

NC12CC3CC(CC(C3)C1)C2

InChI

InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2

Molecular Formula

C10H17N

HBD / HBA

1 / 1

可旋转键数

0

重原子数

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

An antiviral and dopaminergic medication with dual uses: it was originally developed to prevent influenza A infection, and it also treats the symptoms of Parkinson's disease and drug-induced movement disorders by increasing dopamine activity and blocking NMDA glutamate receptors in the brain. It can reduce involuntary movements (dyskinesias) in Parkinson's patients.

Yes, Amantadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL660. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2130. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Amantadine 在 PillFYI 上

结构

快速数据

分子式: C10H17N
同义词: 4

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.